Application of BMPR1B inhibitor in induced development and induced culture medium

By using a BMPR1B inhibitor to form a complex with BMPR1B in the induction culture medium, the problem of pluripotent stem cell directed differentiation was solved, achieving efficient differentiation into neural lineage cells and providing therapeutic possibilities for neurodegenerative diseases and nerve injuries.

CN118995607APending Publication Date: 2024-11-22IREGENE THERAPEUTICS (SUZHOU) CO LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202310574789.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-22
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing technologies struggle to efficiently control the BMPR1B receptor to achieve targeted differentiation of pluripotent stem cells into neural lineage cells for the treatment of neurodegenerative diseases and nerve injuries.

Method used

An induction culture medium containing a BMPR1B inhibitor is provided, which regulates the expression of downstream genes and promotes the differentiation of pluripotent stem cells into neural lineage cells by forming a stable complex with BMPR1B.

Benefits of technology

This achievement enables highly efficient directed differentiation of pluripotent stem cells into neural lineage cells, providing a new approach for the treatment of neurodegenerative diseases and nerve injuries.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995607A_ABST
    Figure CN118995607A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicine, in particular to application of a BMPR1B inhibitor in induced development, an induction culture medium and an induction method. The induction medium comprises a BMPR1B inhibitor which has a structure as shown in a formula I, or is pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorphic substance, isotope label, isomeride or prodrug of the structure as shown in the formula I. The BMPR1B inhibitor contained in the culture medium is a pyrazole formyl piperazinone compound with a special structure design, and can form a stable complex with BMPR1B through hydrogen bond interaction, hydrophobic interaction and other modes, so that BMPR1B is controlled, downstream gene expression and physiological process regulation and control are realized, and the BMPR1B gene expression and physiological process regulation and control efficiency is improved. Therefore, the pluripotent stem cells can be efficiently and directionally differentiated to the neuropedigree cells. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomedicine, and in particular to an application of a BMPR1B inhibitor in inducing development and an induction culture medium. Background Art

[0002] Transforming growth factor-β (TGF-β) belongs to the TGF-β superfamily and plays a vital role in regulating cell growth and differentiation. There are two main types of cell membrane receptors for TGF-β: TGF-β type I receptor and TGF-β type II receptor. In vertebrates, there are seven known type I receptors (activin-receptor like kinases), namely: ALK1 (ACVRL1), ALK2 (ACVR1), ALK3 (BMPR1A), ALK4 (ACVR1B), ALK5 (TGFBR1), ALK6 (BMPR1B) and ALK7 (ACVR1C); five type II receptors, namely: TGFβRⅡ, ACTRⅡ, ACTRⅡB, BMPRⅡ and AMHRⅡ.

[0003] Among them, ALK6, which belongs to the type I receptor, namely BMPR1B (bone morphogenetic protein receptor, type IB), is an important transmembrane receptor protein that plays an important role in regulating osteogenic differentiation, cell proliferation, and ovarian follicle development. Therefore, how to artificially control BMPR1B and then achieve the regulation of downstream gene expression and physiological processes is a research hotspot in the field of biomedicine. Summary of the invention

[0004] Based on this, it is necessary to provide an induction culture medium, an induction method and the application of a BMPR1B inhibitor.

[0005] A first aspect of the present invention provides an induction medium comprising a BMPR1B inhibitor;

[0006] The BMPR1B inhibitor has a structure as shown in Formula I or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope label, isomer or prodrug of the structure as shown in Formula I;

[0007]

[0008] Wherein, ring A is selected from any of the following structures:

[0009]

[0010] Y is -(CH2) n -, n is 0, 1, 2 or 3;

[0011] R 1 Selected from -H, -D, unsubstituted or R 2 Substituted C1-C6 alkyl, C1-C6 alkoxy, C6-C 10 Aryl or C3~C 10 heteroaryl;

[0012] R 2 Selected from -F, -Cl, -Br, -I, -OH, -COOH, C1-C6 alkyl or C1-C6 alkoxy;

[0013] “*” indicates the attachment site.

[0014] The culture medium provided by the present invention contains a BMPR1B inhibitor, which is a pyrazole carbonyl piperazinone compound with a special structural design, which can form a relatively stable complex with BMPR1B through hydrogen bond interaction and hydrophobic interaction, thereby controlling BMPR1B, and then achieving regulation of downstream gene expression and physiological processes, so that pluripotent stem cells can efficiently and directionally differentiate into neural lineage cells, providing a possible way for stem cell biology to treat neurodegenerative diseases and neural damage. The second aspect of the present invention provides a method for inducing pluripotent stem cells to differentiate into neural lineage cells, comprising the following steps:

[0015] The pluripotent stem cells are cultured adherently using the aforementioned induction medium to obtain neural lineage cells.

[0016] The third aspect of the present invention provides the use of the aforementioned BMPR1B inhibitor in inducing differentiation of pluripotent stem cells into neural lineage cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 To screen and analyze the specificity of pyrazole piperazinone compounds binding to targets based on kinase activity; Figure 1 A shows the effect analysis of compound II-1 on the enzymatic activity of 330 kinases; Figure 1 B and 1C show the results of the kinase activity test of compound II-1 on TGFBR1 and BMPR2 at different concentrations;

[0018] Figure 2 The information of the interaction between the compound and BMPR1B in the pyrazole piperazinone compound-BMPR1B complex displayed by PyMol software; Figure 2 The compound in A is II-13, Figure 2 The compound in B is II-11, Figure 2 The compound in C is II-2, Figure 2 The compound in D is II-1;

[0019] Figure 3 The specific situation of the Western blot experiment in Example 3 is shown; wherein, "12hr" means 12 hours, "24hr" means 24 hours, and "36hr" means 36 hours;

[0020] Figure 4 The changes in mRNA expression levels of marker genes after H9 cells were treated with different concentrations of compound II-1 were shown; Figure 4 A represents the mRNA expression level of NANOG gene after 7 days of treatment; Figure 4 B shows the mRNA expression level of PAX6 gene after 7 days of treatment; Figure 4 C represents the mRNA expression level of NANOG gene after 14 days of treatment; Figure 4 D represents the mRNA expression level of PAX6 gene after 14 days of treatment;

[0021] Figure 5 The changes in mRNA expression levels of marker genes after H1 cells were treated with different concentrations of compound II-13 were shown; Figure 5 A represents the mRNA expression level of MAP2 gene after 7 days of treatment; Figure 5 B shows the mRNA expression level of SOX9 gene after 7 days of treatment; Figure 5 C represents the mRNA expression level of MAP2 gene after 14 days of treatment; Figure 5 D shows the mRNA expression level of SOX9 gene after 14 days of treatment;

[0022] Figure 6 The changes in mRNA expression levels of marker genes after treatment of induced pluripotent stem cells (iPSCs) with different concentrations of compound II-13 are shown; Figure 6 A represents the mRNA expression level of SOX1 gene after 7 days of treatment; Figure 6 B shows the mRNA expression level of SOX5 gene after 7 days of treatment; Figure 6 C represents the mRNA expression level of VIMENTIN (VIM) gene after 7 days of treatment; Figure 6 D shows the mRNA expression level of SOX1 gene after 14 days of treatment; Figure 6 E represents the mRNA expression level of SOX5 gene after 14 days of treatment; Figure 6 F represents the mRNA expression level of VIMENTIN (VIM) gene after 14 days of treatment. DETAILED DESCRIPTION

[0023] In order to facilitate the understanding of the present invention, the present invention will be described more fully below with reference to the relevant drawings. The preferred embodiments of the present invention are given in the drawings. However, the present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.

[0024] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.

[0025] In the present invention, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.

[0026] In the present invention, when it comes to numerical ranges, unless otherwise specified, the above numerical ranges are deemed to be continuous and include the minimum and maximum values ​​of the range, as well as each value between such minimum and maximum values. Further, when a range refers to an integer, each integer between the minimum and maximum values ​​of the range is included. In addition, when multiple ranges are provided to describe features or characteristics, the ranges can be merged. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all subranges included therein.

[0027] The percentage content involved in the present invention, unless otherwise specified, refers to mass percentage for solid-liquid mixing and solid-solid mixing, and refers to volume percentage for liquid-liquid mixing.

[0028] The percentage concentrations involved in the present invention, unless otherwise specified, refer to the final concentration. The final concentration refers to the proportion of the added component in the system after the addition of the component.

[0029] The temperature parameters in the present invention, if not specifically limited, allow for both constant temperature treatment and treatment within a certain temperature range. The constant temperature treatment allows the temperature to fluctuate within the precision range controlled by the instrument.

[0030] Explanation of terms

[0031] The term "alkyl" refers to a monovalent residue formed by the loss of a hydrogen atom from a saturated hydrocarbon containing a primary (normal) carbon atom, or a secondary carbon atom, or a tertiary carbon atom, or a quaternary carbon atom, or a combination thereof. Phrases containing this term, for example, "C1-C6 alkyl" refers to an alkyl group containing 1 to 6 carbon atoms, and each occurrence can be independently C1 alkyl, C2 alkyl, C3 alkyl, C4 alkyl, C5 alkyl or C6 alkyl. Suitable examples include, but are not limited to: methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1-propyl (n-Pr, n-propyl, -CH2CH2CH3), 2-propyl (i-Pr, i-propyl, -CH(CH3)2), 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methyl-1-propyl (i-Bu, i-butyl, -CH2CH(CH3)2), 2-butyl (s-Bu, s-butyl, -C H(CH3)CH2CH3), 2-methyl-2-propyl (t-Bu, t-butyl, -C(CH3)3), 1-pentyl (n-pentyl, -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-methyl -1-butyl (-CH2CH2CH(CH3)2), 2-methyl-1-butyl (-CH2CH(CH3)CH2CH3), 1-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl ( -CH(CH3)CH(CH3)CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2) and 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3.

[0032] The term "alkoxy" refers to a group having the structure -O-alkyl, i.e., an alkyl group as defined above is connected to an adjacent group via an oxygen atom. Phrases containing the term, for example, "C1-C6 alkoxy" means that the alkyl portion contains 1 to 6 carbon atoms, and each occurrence may be independently C1 alkoxy, C4 alkoxy, C5 alkoxy or C6 alkoxy. Suitable examples include, but are not limited to, methoxy (-O-CH3 or -OMe), ethoxy (-O-CH2CH3 or -OEt) and tert-butoxy (-OC(CH3)3 or -OtBu).

[0033] "Aryl" refers to an aromatic hydrocarbon group derived from an aromatic ring compound by removing a hydrogen atom. It can be a monocyclic aromatic group, a condensed aromatic group, or a polycyclic aromatic group. For polycyclic rings, at least one is an aromatic ring system. For example, "C6-C 10 "Aryl" refers to an aromatic group containing 6 to 10 carbon atoms, and each occurrence can be independently C6 aromatic group, C7 aromatic group, C8 aromatic group, C9 aromatic group or C 10 Suitable examples include, but are not limited to, benzene, biphenyl, naphthalene and their derivatives.

[0034] "Heteroaryl" means that at least one carbon atom in an aryl or cyclopentadienyl group is replaced by a non-carbon atom, such as a nitrogen atom, an oxygen atom, or a sulfur atom. 10 The term "heteroaryl" refers to a heteroaryl group containing 3 to 10 carbon atoms, which may be independently C3 heteroaryl, C4 heteroaryl, C5 heteroaryl, C6 heteroaryl, C7 heteroaryl or C8 heteroaryl at each occurrence. Suitable examples include, but are not limited to, furan, benzofuran, thiophene, benzothiophene, pyrrole, pyrazole, triazole, imidazole, oxazole, oxadiazole, thiazole, tetrazole, indole, carbazole, pyrroloimidazole, pyrrolopyrrole, thienopyrrole, thienothiophene, furopyrrole, furanofuran, thienofuran, benzisoxazole, benzisothiazole, benzimidazole, pyridine, pyrazine, pyridazine, pyrimidine, triazine, quinoline, isoquinoline, o-naphthyridine, quinoxaline, phenanthridine, primary idine, quinazoline and quinazolinone.

[0035] "Prodrugs" as described herein refer to any compound that produces a drug, i.e., an active ingredient, due to a spontaneous chemical reaction, an enzyme-catalyzed chemical reaction, photolysis, and / or a metabolic chemical reaction when administered to an organism. Prodrugs are therefore covalently modified analogs or latent forms of therapeutically active compounds. Suitable examples include, but are not limited to, carboxylate, carbonate, phosphate, nitrate, sulfate, sulfone, sulfoxide, amide, carbamate, azo compound, phosphoramide, glucoside, ether, acetal, etc. forms of the compound.

[0036] "Pharmaceutically acceptable" refers to those ligands, materials, compositions, and / or dosage forms that are suitable for administration to a patient within the scope of sound medical judgment and commensurate with a reasonable benefit / risk ratio.

[0037] "Pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. As used herein, the language "pharmaceutically acceptable carrier" includes buffers, sterile water for injection, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are compatible with drug administration. Each carrier must be "pharmaceutically acceptable" in the sense of being compatible with the other ingredients in the formulation and not harmful to the patient. Suitable examples include, but are not limited to: (1) sugars such as lactose, glucose and sucrose; (2) starches such as corn starch, potato starch and substituted or unsubstituted β-cyclodextrins; (3) cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients such as cocoa butter and suppository waxes; (9) oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn starch, etc. Rice oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffered saline; and (21) other non-toxic compatible substances used in pharmaceutical formulations.

[0038] "Pharmaceutically acceptable salt" refers to a salt suitable for use as a drug formed by any compound in the structure shown and an acid or base. Pharmaceutically acceptable salts include inorganic salts and organic salts. Among them, one type of salt is a salt formed by the compound of the present invention and an acid. Acids suitable for forming salts include but are not limited to: inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, and phosphoric acid; organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, and naphthalenesulfonic acid; and amino acids such as proline, phenylalanine, aspartic acid, and glutamic acid. Another type of salt is a salt formed by a compound of the present invention and a base. Suitable bases for forming salts include but are not limited to alkali metal salts (e.g., sodium salts or potassium salts), alkaline earth metal salts (e.g., magnesium salts or calcium salts), ammonium salts (e.g., lower alkanolammonium salts and other pharmaceutically acceptable amine salts), for example, methylamine salts, ethylamine salts, propylamine salts, dimethylamine salts, trimethylamine salts, diethylamine salts, triethylamine salts, tert-butylamine salts, ethylenediamine salts, hydroxyethylamine salts, dihydroxyethylamine salts, trihydroxyethylamine salts, and amine salts formed from morpholine, piperazine, and lysine, respectively.

[0039] "Pharmaceutically acceptable esters and amides" refer to esters or amides formed by any compound in the structure shown and other compounds that are suitable for use as drugs. Pharmaceutically acceptable esters include organic esters and inorganic esters.

[0040] In the case where the compound represented by Formula I has a carboxyl group, the compound represented by Formula I or its active derivatives (such as acid chloride, mixed acid anhydride, etc.) can be reacted with the corresponding alcohol (such as C1-C6 alcohol, etc.) or its active derivatives (such as (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl body, (pivaloyloxy)methyl body, benzofuranone body, (isopropoxycarbonyl)oxymethyl body, etc.), or ammonia or the corresponding amine (mono-C1-C6 alkylamine- or di-C1-C6 alkylamine, etc.) according to conventional methods (condensation reaction of carboxylic acids with alcohols or amines); the ester of the compound represented by Formula I can be reacted with the corresponding alcohol (such as C1-C6 alcohol, etc.) (ester exchange reaction), or ammonia or the corresponding amine (mono-C1-C6 alkylamine or di-C1-C6 alkylamine, etc.) (amidation reaction). or reacting the alkali metal salt of the compound shown in Formula I with the corresponding halide (e.g., C1-C6 alkyl chloride or bromide, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl chloride or bromide, (pivaloyloxy) methyl chloride or bromide, benzofuranone chloride or bromide, [(isopropoxycarbonyl) oxygen] methyl chloride or bromide, etc.) to prepare pharmaceutically acceptable esters or amides. Similarly, in the case where the compound shown in Formula I has a hydroxyl group, the compound shown in Formula I can be subjected to a condensation reaction with a carboxylic acid, an acyl chloride, an acid anhydride, etc. according to conventional methods to obtain pharmaceutically acceptable esters.

[0041] The esters may be, for example, C1-C6 alkyl esters such as methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, sec-butyl ester, tert-butyl ester, pentyl ester, hexyl ester; C3-C6 cycloalkyl esters such as cyclopentyl ester and cyclohexyl ester; C6-C6 cycloalkyl esters such as phenyl ester and naphthyl ester; 10 Aromatic esters; benzyl ester, phenethyl ester, α-methylbenzyl ester, 3-phenylpropyl ester, 4-phenylbutyl ester, 6-phenylhexyl ester, diphenylmethyl ester, triphenylmethyl ester, etc. C6-C 10 Aryl C1-C6 alkyl esters; or esters that can be hydrolyzed in vivo, such as (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, (pivaloyloxy)methyl ester, benzofuranonyl ester, [(isopropoxycarbonyl)oxy]methyl ester, [(cyclohexyloxycarbonyl)oxy]methyl ester, and 1-[(cyclohexyloxycarbonyl)oxy]ethyl ester.

[0042] The aforementioned amides may be, for example, amide (-CONH2); mono-C1-C6 alkylamides or mono-C3-C6 cycloalkylamides such as N-formamide, N-acetamide, N-propionamide, N-isopropylamide, N-butyramide, N-sec-butyramide, N-tert-butyramide, N-pentanamide, N-hexanamide, N-cyclopropanamide, N-cyclopentanamide, and N-cyclohexanamide; or N,N-diformamide, N,N-diethylamide, N,N-dipropylamide, N,N-dimethyl ... N,N-diisopropylamide, N-methyl-N-acetamide, N-methyl-N-propionamide, N-methyl-N-butyramide, N-ethyl-N-propionamide, N-ethyl-N-butyramide, N-butyl-N-cyclopentylamide, N-ethyl-N-cyclopropionamide, N,N-dicyclohexylamide and other di-C1-C6 alkylamides, N-C1-C6 alkyl-N-C3-C6 cycloalkylamides or di-C3-C6 cycloalkylamides.

[0043] "Solvate" refers to a complex formed by the compound represented by general formula (I) and solvent molecules coordinated to form a specific ratio. "Hydrate" refers to a complex formed by the compound of the present invention coordinated with water.

[0044] "Active metabolite" refers to an active derivative of a compound that is formed when the compound is metabolized.

[0045] "Polymorphs" refers to compounds of the invention that exist in different crystalline lattice forms.

[0046] "Isotope-labeled" refers to a compound of the present invention that is labeled with an isotope. For example, the isotopes in the compound of the present invention may include various isotopes of elements such as H, C, N, O, P, F, S, etc. 2 H. 3 H. 13 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 S.

[0047] "Isomers" refer to isomers produced by different spatial arrangements of atoms in a molecule. The compounds of the present invention contain structures such as asymmetric or chiral centers, double bonds, etc. Therefore, the compounds of the present invention may include multiple isomeric forms such as optical isomers, geometric isomers, tautomers, atropisomers, etc. These isomers and their single isomers, racemates, etc. are all included in the scope of the present invention. For example, for optical isomers, optically active (R)- and (S)-isomers and D and L isomers can be prepared by chiral resolution, chiral synthesis or chiral reagents or other conventional techniques. For example, it can be converted into diastereomers by reaction with appropriate optically active substances (such as chiral alcohols or Mosher's acyl chlorides), which are separated and converted (such as hydrolyzed) into corresponding single isomers. For another example, separation can also be carried out by chromatographic columns.

[0048] Neurodegenerative diseases and neural damage have fatal effects on human health and are often difficult to cure. With the development of stem cell biology, neuroscience and reprogramming technology, some effective treatments have been developed. For example, stem cell replacement therapy can be used for central and peripheral nervous system diseases and injuries to regenerate affected neural tissue with neurons and other neural cells. One of the main strategies to achieve the above ultimate goal is to reshape the normal development of the nervous system by activating the endogenous regenerative capacity of neural stem cells or transplanting neural or embryonic cells. Although the use of stem cells in neurological diseases is very popular, there are also some severe challenges. For example, how to control the efficient and stable directional differentiation of stem cells has always been a problem that the field of stem cell biology research aims to solve.

[0049] Based on the above background, the first aspect of the present invention provides an induction medium comprising a BMPR1B inhibitor;

[0050] The BMPR1B inhibitor has a structure as shown in Formula I, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled, isomer or prodrug of the structure as shown in Formula I;

[0051]

[0052] Wherein, ring A is selected from any of the following structures:

[0053]

[0054] Y is -(CH2) n -, n is 0, 1, 2 or 3;

[0055] R 1 Selected from -H, -D, unsubstituted or R 2 Substituted C1-C6 alkyl, C1-C6 alkoxy, C6-C10 Aryl or C3~C 10 heteroaryl;

[0056] R 2 Selected from -F, -Cl, -Br, -I, -OH, -COOH, C1-C6 alkyl or C1-C6 alkoxy;

[0057] “*” indicates the attachment site.

[0058] The culture medium provided by the present invention contains a BMPR1B inhibitor, which is a pyrazole piperazinone compound with a special structural design. The BMPR1B inhibitor can form a relatively stable complex with BMPR1B through hydrogen bond interaction and hydrophobic interaction, thereby controlling BMPR1B, and further achieving regulation of downstream gene expression and physiological processes, so that pluripotent stem cells can efficiently and directionally differentiate into neural lineage cells, providing a possible way for the use of stem cell biology in the treatment of neurodegenerative diseases and neural damage.

[0059] In some embodiments, Y is -(CH2) n -, n is 0, 1 or 2; preferably, Y is -(CH2) n -, n is 0 or 1; further preferably, Y is -(CH2) n -, n is 0 or 1.

[0060] In some embodiments, R 1 Selected from -H, -D, unsubstituted or R 2 Substituted C1-C6 alkyl, C6-C 10 Aryl or C3~C 10 Heteroaryl; preferably, R 1 Selected from -H, -D, unsubstituted or R 2 substituted C3-C6 heteroaryl; further preferably, R 1 Selected from -H, -D, unsubstituted or R 2 substituted furan, thiophene, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, pyran, thiopyran, pyridine, pyridazine or pyrimidine; more preferably, R 1 Selected from -H, -D, or any of the following substituents:

[0061]

[0062] Wherein, “*” indicates the connection site.

[0063] When R 1When selected from heteroaryl groups, especially heteroaryl groups substituted with methyl or hydroxyl groups, the formed pyrazolyl piperazinone compounds have higher binding energy with the docking target of BMPR1B and lower physiological toxicity, which is beneficial to improving the efficacy and biocompatibility of pyrazolyl piperazinone compounds as BMPR1B inhibitors.

[0064] In some embodiments, R 2 is selected from -OH or C1-C6 alkyl; preferably, R 2 is selected from -OH or C1-C4 alkyl; further preferably, R 2 Selected from -OH, methyl, ethyl, n-propyl or isopropyl.

[0065] In some embodiments, the BMPR1B inhibitor has a structure as shown in any one of Formulas I-1 to I-13, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled, isomer or prodrug of the structure as shown in any one of Formulas I-1 to I-13;

[0066]

[0067] In some embodiments, the BMPR1B inhibitor has a structure as shown in Formula II, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled, isomer or prodrug of the structure as shown in Formula II;

[0068]

[0069] Among them, ring A, Y and R 1 As defined in any of the preceding embodiments.

[0070] In some embodiments, the BMPR1B inhibitor has a structure as shown in any one of Formulas II-1 to II-13, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled, isomer or prodrug of the structure as shown in any one of Formulas II-1 to II-13;

[0071]

[0072] In some embodiments, the concentration of the BMPR1B inhibitor is 1 μM to 50 μM, preferably, the concentration of the BMPR1B inhibitor is 1 μM to 20 μM, and further preferably, the concentration of the BMPR1B inhibitor is 1 μM to 10 μM. Optionally, the concentration of the BMPR1B inhibitor can be, for example, 2.5 μM, 5 μM, 7.5 μM, 10 μM, 12.5 μM, 15 μM, 17.5 μM, 20 μM, 25 μM, 30 μM, 35 μM, 40 μM or 45 μM. The concentration of a suitable BMPR1B inhibitor can more efficiently promote the directed differentiation of pluripotent stem cells into neural lineage cells without causing damage.

[0073] In some embodiments, the induction medium further comprises one or more of a basal medium, a growth factor, an inorganic salt, and an additive;

[0074] Among them, the growth factors include one or more of vitamins, progesterone, 1,4-butanediamine and insulin;

[0075] The additives include one or more of piperidinol oxide, luteolin, D(+)-galactose and recombinant human transferrin.

[0076] In some embodiments, the induction medium satisfies one or more of the following conditions:

[0077] (1) The basal medium is DMEM medium or DMEM-F12 medium, and the basal medium is supplemented with minimum essential medium non-essential amino acids;

[0078] (2) Vitamins include one or more of vitamin E, vitamin B12 and vitamin C;

[0079] (3) Inorganic salts include one or more of sodium chloride and sodium selenite.

[0080] In some embodiments, the induction medium satisfies one or more of the following conditions:

[0081] (1) Growth factors include vitamins, 2.0 ng / mL to 15 ng / mL of progesterone, 2 μg / mL to -50 μg / mL of 1,4-butanediamine, and 5 mg / L to 40 mg / L of insulin, and vitamins include 0.1 μg / mL to 15 μg / mL of vitamin E, 0.5 μM to 2.4 μM of vitamin B12, and 32 mg / L to 128 mg / L of vitamin C;

[0082] (2) Inorganic salts include 0.5 g / L sodium chloride and 13.6 μg / L sodium selenite;

[0083] (3) The additives include 10 μM to 200 μM piperidinol oxide, 5 μM to 150 μM luteolin, 5 μg / mL to 25 μg / mL D(+)-galactose, and 50 ng / mL to 200 ng / mL recombinant human transferrin.

[0084] In some embodiments, the induction medium satisfies one or more of the following conditions:

[0085] (1) Growth factors include vitamins, 6.3 ng / mL progesterone, 23 μg / mL 1,4-butanediamine, and 22 mg / L insulin, and vitamins include 1 μg / mL vitamin E, 1.2 μM vitamin B12, and 64 mg / L vitamin C;

[0086] (2) Inorganic salts include 0.5 g / L sodium chloride and 13.6 μg / L sodium selenite;

[0087] (3) Additives included 50 μM piperidinol oxide, 60 μM luteolin, 12.5 μg / mL D(+)-galactose, and 100 ng / mL recombinant human transferrin.

[0088] A second aspect of the present invention provides a method for inducing pluripotent stem cells to differentiate into neural lineage cells, comprising the following steps:

[0089] Adhesion culture of pluripotent stem cells is performed using the induction medium described in any of the aforementioned embodiments to obtain neural lineage cells.

[0090] In some embodiments, NANOG is used as a marker for identifying pluripotent stem cells, and PAX6 is used as a marker for identifying neural lineage cells. Since NANOG is only expressed in pluripotent stem cells, and PAX6 is only expressed in neural lineage cells, the selection of these two as identification markers can quantitatively track the differentiation of pluripotent stem cells into neural lineage cells and verify the induction results.

[0091] In some embodiments, the adherent culture is performed in the presence of a basement membrane preparation. Preferably, the basement membrane preparation comprises one or more of basement glue, laminin and vitronectin.

[0092] In some embodiments, the pluripotent stem cells are mammalian pluripotent stem cells. Optionally, the pluripotent stem cells are human pluripotent stem cells, which can be, for example, H9 cell lines or H1 cell lines, or human induced pluripotent stem cells (for example, the method of CN109628383B can be used to obtain them by reprogramming from CD34+ cells).

[0093] In some embodiments, the neural lineage cells include one or more of neural progenitor cells, neurons, astrocytes, and oligodendrocytes.

[0094] The third aspect of the present invention provides use of the BMPR1B inhibitor mentioned in the induction medium described in any of the aforementioned embodiments in inducing differentiation of pluripotent stem cells into neural lineage cells.

[0095] Compound synthesis (in the following content, if there is a discrepancy between the compound name and the structural formula, the structural formula shall prevail):

[0096] Synthetic Route A

[0097]

[0098] The intermediate M1-n (0.12 mmol), (4aS, 8aS)-octahydroquinolin-2(1H)-one (M2, 15 mg, 0.1 mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, 380 mg, 1 mmol) were mixed, and then N,N-diisopropylethylamine (DIEA, 2 mL) and N,N-dimethylformamide (DMF, 20 mL) were added and stirred at room temperature for 18 hours. Ethyl acetate and water were added to the reaction mixture, and the organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate: hexane = 3:7) to obtain the target product II-n.

[0099] Compounds II-1 and II-13 were obtained by synthetic route A:

[0100] II-1:

[0101] (4aS,8aS)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0102] (4aS,8aS)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (12 mg, 41%), LC-MS m / z=289.2 [M+H] + .

[0103] II-13:

[0104] (4aS,8aS)-4-(1H-indazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0105] (4aS,8aS)-4-(1H-indazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (17 mg, 57%), LC-MS m / z=299.2 [M+H] + .

[0106] Synthetic route B

[0107]

[0108] Compound II-12 was obtained by synthetic route B:

[0109] II-12:

[0110] (4aS,8aS)-4-(4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0111] (4aS,8aS)-4-(4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0112] (1) To a solution of 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (M3-1, 0.167 g, 1 mmol) in 2 mL 1 mol / L NaOH and 0.6 mL 1,4-dioxane was added dropwise 1.5 mL 1,4-dioxane solution containing 0.25 g (1.1 mmol) of di-tert-butyl dicarbonate (Boc2O) at 0°C. The reaction mixture was stirred at 0°C for 0.5 h and then reacted at room temperature overnight, maintaining pH 8-9. After the reaction, the mixture was diluted with 5 ml H2O and extracted with n-hexane. The aqueous phase was acidified to pH 2-3 with citric acid and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 5-(tert-butoxycarbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (M3-2, 200 mg, 75%), LC-MS m / z=268.1 [M+H] + ;

[0113] (2) M3-2 (20 mg, 0.075 mmol) was mixed with (4aS, 8aS)-octahydroquinolin-2(1H)-one (M2, 15 mg, 0.1 mmol) and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, 38 mg, 0.1 mmol), and N,N-diisopropylethylamine (DIEA, 0.2 mL) and N,N-dimethylformamide (DMF, 2 mL) were added, and the mixture was stirred at room temperature for 18 hours. Ethyl acetate and water were added to the reaction mixture, and the organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate: hexane = 3:7) to give tert-butyl 3-((4aS, 8aS)-3-oxodeoxyquinoline-1-carbonyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (M3-3, 18 mg, 60%), LC-MS m / z = 404.2 [M+H] + ;

[0114] (3) M3-3 (18 mg, 0.04 mmol) and trifluoroacetic acid (TFA, 35 mg, 0.3 mmol) were added to 2 mL of dichloromethane (DCM), and stirred at room temperature for half an hour. Ethyl acetate and water were added to the reaction mixture, and the organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure. II-12 (13 mg, 96%) was obtained, LC-MS m / z=304.2 [M+H] + .

[0115] Synthetic Route C

[0116]

[0117] (1) Sodium hydride (60% suspension, 1.07 g, 26.9 mmol) dissolved in tetrahydrofuran (5 mL) was cooled to 0°C, and a solution of M1-n (21.5 mmol) in tetrahydrofuran (50 mL) was added dropwise thereto over 15 minutes, and the mixture was stirred at 0°C for 1 hour. A solution of (2-(chloromethoxy)ethyl)trimethylsilane (M4, 4.76 mL, 26.9 mmol) in tetrahydrofuran (50 mL) was added dropwise to the mixture, and the mixture was stirred at room temperature for 48 hours. Water and ethyl acetate were slowly added to the reaction mixture, the organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure to obtain M5-n;

[0118] (2) In a 20 mL reactor, R 1 -YX (0.698mmol, wherein X represents halogen, R 1and Y are as defined above), (4aS, 8aS)-octahydroquinoxaline-2(1H)-one (M2, 108 mg, 0.698 mmol, 1.0 eq.), cesium carbonate (796 mg, 2.443 mmol, 2.5 eq.), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (20 mg, 0.035 mmol, 0.05 eq.) and palladium acetate (7.84 mg, 0.035 mmol, 0.05 eq.) were dissolved in tetrahydrofuran (3 mL) and bubbling with nitrogen for 10 minutes. The reaction was heated to 70°C and maintained for 90 minutes, the mixture was filtered, washed with dichloromethane and concentrated. The residue was purified by silica gel column chromatography (0-10% ethyl acetate / dichloromethane) to give M6-n;

[0119] (3) M6-n (1.0 mmol, 1.0 eq) was dissolved in dichloromethane (10 mL), and M5-n (1.2 mmol, 1.2 eq.), triethylamine (200 mg, 2.0 mmol, 2.0 eq.) and tetramethylurea of ​​hexafluorophosphate azobenzotriazole (570 mg, 1.5 mmol, 1.5 eq.) were added to the mixture, and stirred overnight. The reaction was monitored by thin layer chromatography. When the reactant was no longer visible, the mixture was diluted with dichloromethane, washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (2:1, petroleum ether: ethyl acetate) to obtain M7-n;

[0120] (4) Triethylsilane (2.30 g, 19.8 mmol) was added to a solution of M7-n (3.95 mmol) in tetrahydrofuran (39.5 mL) at 5°C, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated, washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 20-100%) to obtain the target product II-n.

[0121] Compounds II-2 to II-10 were obtained via synthetic route C:

[0122] II-2:

[0123] (4aS,8aS)-1-(3-methylthiophen-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0124] (4aS,8aS)-1-(3-methylthiophen-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1504 mg, 99%). LC-MS m / z=384.2[M+H] + .

[0125] II-3:

[0126] (4aS,8aS)-1-(2-methyloxazol-4-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)oct ahydroquinoxalin-2(1H)-one

[0127] (4aS,8aS)-1-(2-methyloxazol-4-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1445 mg, 99%). LC-MS m / z=370.2[M+H] + .

[0128] II-4:

[0129] (4aS,8aS)-1-(3-methylisothiazol-5-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0130] (4aS,8aS)-1-(3-methylisothiazol-5-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1507 mg, 99%). LC-MS m / z=386.2[M+H] + .

[0131] II-5:

[0132] (4aS,8aS)-1-(2-methylpyridin-4-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)oct ahydroquinoxalin-2(1H)-one

[0133] (4aS,8aS)-1-(2-methylpyridin-4-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1469 mg, 98%). LC-MS m / z=380.2[M+H] + .

[0134] II-6:

[0135] (4aS,8aS)-1-(6-methylpyridin-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)oct ahydroquinoxalin-2(1H)-one

[0136] (4aS,8aS)-1-(6-methylpyridin-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1484 mg, 99%). LC-MS m / z=380.2[M+H] + .

[0137] II-7:

[0138] (4aS,8aS)-1-(6-hydroxypyridin-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0139] (4aS,8aS)-1-(6-hydroxypyridin-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1491 mg, 99%). LC-MS m / z=382.2[M+H] + .

[0140] II-8:

[0141] (4aS,8aS)-1-(4-hydroxypyridin-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0142] (4aS,8aS)-1-(4-hydroxypyridin-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1491 mg, 99%). LC-MS m / z=382.2[M+H] + .

[0143] II-9:

[0144] (4aS,8aS)-1-(2-methylpyrimidin-4-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0145] (4aS,8aS)-1-(2-methylpyrimidin-4-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1488 mg, 99%). LC-MS m / z=381.2[M+H] + .

[0146] II-10:

[0147] (4aS,8aS)-1-(6-methylpyridazin-3-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0148] (4aS,8aS)-1-(6-methylpyridazin-3-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1413 mg, 94%). LC-MS m / z=381.2[M+H] + .

[0149] Synthetic route D

[0150]

[0151]

[0152] Compound II-11 was obtained via synthetic route D:

[0153] II-11:

[0154] (4aS,8aS)-1-((5-methyl-1H-pyrazol-4-yl)methyl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0155] (4aS,8aS)-1-((5-methyl-1H-pyrazol-4-yl)methyl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0156] (1) Sodium hydride (60% suspension, 1.07 g, 26.9 mmol) dissolved in tetrahydrofuran (5 mL) was cooled to 0°C, and a solution of 5-methyl-1H-pyrazole-4-carboxaldehyde (M8-1, 2.37 g, 21.5 mmol) in tetrahydrofuran (50 mL) was added dropwise thereto over 15 minutes, and the mixture was stirred at 0°C for 1 hour. A solution of (2-(chloromethoxy)ethyl)trimethylsilane (M4, 4.76 mL, 26.9 mmol) in tetrahydrofuran (50 mL) was added dropwise to the mixture, and the mixture was stirred at room temperature for 48 hours. Water and ethyl acetate were slowly added to the reaction mixture, and the organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure to obtain 5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-4-carboxaldehyde (M8-2, 4.96 g, 96%). LC-MS m / z=240.1[M+H] + ;

[0157] (2) In a 20 mL reactor, M8-2 (168 mg, 0.698 mmol), (4aS, 8aS)-octahydroquinoxalin-2(1H)-one (M2, 108 mg, 0.698 mmol, 1.0 eq.), cesium carbonate (796 mg, 2.443 mmol, 2.5 eq.), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (20 mg, 0.035 mmol, 0.05 eq.) and palladium acetate (7.84 mg, 0.035 mmol, 0.05 eq.) were dissolved in tetrahydrofuran (3 mL) and nitrogen was bubbled for 10 minutes. The reaction was heated to 70° C. and maintained for 90 minutes, and the mixture was filtered, washed with dichloromethane and concentrated. The residue was purified by silica gel column chromatography (0-10% ethyl acetate / dichloromethane) to give (4aS,8aS)-1-((5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)methyl)octahydroquinoxalin-2(1H)-one (M8-3, 244 mg, 92.2%). LC-MS m / z=378.3[M+H] +;

[0158] (3) M8-3 (379 mg, 1.0 mmol, 1.0 eq) was dissolved in dichloromethane (10 mL), 1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,5,6-tetrahydrocyclopenta-pyrazole-3-carboxylic acid (M8-4, 339 mg, 1.2 mmol, 1.2 eq.), triethylamine (200 mg, 2.0 mmol, 2.0 eq.) and tetramethylurea hexafluorophosphate azobenzotriazole (570 mg, 1.5 mmol, 1.5 eq.) were added to the mixture, and the mixture was stirred overnight. The reaction was monitored by thin layer chromatography. When the reactant was no longer visible, the mixture was diluted with dichloromethane, washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (2:1, petroleum ether: ethyl acetate) to give (4aS, 8aS)-1-((5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)methyl)-4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,5,6-tetrahydrocyclopentanopyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (M8-5, 424 mg, 66%). LC-MS m / z=642.4 [M+H] + ;

[0159] (4) Triethylsilane (2.30 g, 19.8 mmol) was added to a solution of M8-5 (2540 mg, 3.95 mmol) in tetrahydrofuran (39.5 mL) at 5°C, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated, washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 20-100%) to give II-11 (1510 mg, 99%). LC-MS m / z = 383.2 [M+H] + .

[0160] Example 1

[0161] The pyrazole carboxyl piperazinone compounds of the present invention were molecularly docked with the BMPR1B target protein using the AutoDock Vina software to produce 13 docking conformations. The binding energy and ligand efficiency of the optimal docking result of each pyrazole carboxyl piperazinone compound with the BMPR1B target protein were calculated, and the docking results were comprehensively analyzed for pyrrolopyridine molecular screening. The specific docking results are shown in Table 1: The second column of Table 1 is the binding free energy (binding energy) calculated by the AutoDock Vina molecular docking software. The more negative the value, the stronger the binding ability of the compound with the target protein; the predicted value shows that the absolute value of the binding energy of the pyrazole carboxyl piperazinone compounds is much greater than the threshold value 3 set according to the target characteristics.

[0162] The cytotoxicity of the pyrazolyl piperazinone compounds of the present invention was predicted using the eToxPred software, and the toxicity calculation results of each pyrazolyl piperazinone compound are shown in the third column of Table 1. The predicted values ​​show that the toxicity of the pyrazolyl piperazinone compounds is less than the threshold value of 0.58 (greater than 0.58 indicates possible toxicity).

[0163] Table 1. Molecular docking binding energy and molecular toxicity prediction of pyrazole piperazinone compounds

[0164]

[0165] Example 2

[0166] 330 kinase candidates (15-50 nM, 2.5 μL) were mixed with compound II-1 (2.5 mM, 25 nL, prepared in DMSO) and incubated at 25°C for 10 min. Then, a mixture of kinase peptide substrate (0.2 mg / mL; supplier: GenScript) and ATP (10-60 μM; supplier: Promega; product number: V915B) (a total of 2.5 μL, prepared in test buffer) was added to the mixed system, and the mixture was reacted at 25°C for 60-120 min. Finally, HTRF was used. 1 or ADP-Glo 2 Methods The reaction products were quantitatively detected. During the kinase activity test, the consumption of each substrate was less than 10%, and two technical replicates were set for each kinase activity test.

[0167] The results showed that II-1 had a significant inhibitory effect on the kinase activity of BMPR1B ( Figure 1 A; Note: All test results are shown. For ease of reading, the x-axis shows only one kinase name for every 10 kinases), while II-1 at the same concentration had no inhibitory effect on the kinase activity of TGFBR1 and BMPR2, and at different concentrations (the highest concentration was 12.5 μM, 3-fold gradient dilution), it also had no inhibitory effect on TGFBR1 and BMPR2 kinases ( Figure 1 B, C). This result confirmed the specific binding ability of II-1 to the target site.

[0168] In order to investigate the above experimental results from a structural perspective, PyMol software (supplier: ) The structures of the complexes formed by compounds II-1, II-2, II-11, and II-13 with BMPR1B were analyzed. Figure 2As shown, the structure of the complex was obtained by molecular docking. The N- and C-terminal domains of BMPR1B are shown as cartoon models of different shapes, the loop structure of BMPR1 and the loop structure (activation loop) that stimulates catalytic activity are shown as cartoon models of different grayscales, the pyrazole carboxylic acid piperazinone compounds are shown as stick ring models, the interacting amino acid main chain / side chain are shown as stick models, the hydrogen bond interaction is shown as a solid line, and the hydrophobic interaction is shown as a dotted line. This result also shows that the pyrazole carboxylic acid piperazinone compounds have structural characteristics for binding to BMPR1B.

[0169] Example 3

[0170] The inhibitory effect of pyrazolyl piperazinone compounds on the BMP signaling pathway was further verified by Western blot experiments. First, the commercial human pluripotent stem cell line H1 was inoculated into a 6-well cell culture plate with 2 mL of culture medium and 1.5×10^6 cells per well. After one day of culture, the culture medium was replaced and 6 μL of 30uM pyrazolyl piperazinone compound II-I was added. After treating the cells for 12, 24 and 36 hours, the cells were digested and protein samples were prepared. The sample preparation was carried out according to the instructions of the commercial kit (Beyotime Biotechnology; Product No., P0013), and the Western blot analysis method was carried out according to the literature (H. Zhang et al., 2022; N. Zhang et al., 2021). The results showed that within 24 hours of treatment, pyrazolyl piperazinone compound II-I did not inhibit the phosphorylation level of SMAD2 / 3, a downstream signaling protein of the TGF signaling pathway, but showed a significant inhibitory effect on the phosphorylation level of SMAD1 / 5 / 8, a downstream signaling protein of the BMP signaling pathway ( Figure 3 These results further indicate that pyrazolyl piperazinone compound II-I selectively inhibits the BMP signaling pathway, which is consistent with the results of kinase activity assay ( Figure 1 B, C).

[0171] Table 2 Antibody information

[0172]

[0173] Example 4: Induction and identification of neural lineages

[0174] (1) Culture medium formulation

[0175] Dulbecco's modified Eagle's medium (DMEM medium), Minimum Essential Medium Non-Essential Amino Acids (Minimum Essential Medium Non-Essential Amino Acids, Catalog No.: 11140076, Thermo Fisher), piperidinol oxide (4-Hydroxy-TEMPO, concentration is 50μM), D(+)-galactose (D(+)-galactose, concentration is 12.5μg / mL), vitamin E (concentration is 1μg / mL), vitamin B12 (concentration is 1.2μM), vitamin C (concentration is 64mg / L), progesterone (concentration is 6.3ng / mL), 1,4-butanediamine (concentration is 23μg / mL), luteolin (concentration is 60μM), sodium chloride (concentration is 0.5g / L), sodium arsenate (concentration is 13.6μg / L), insulin (concentration is 22μg / mL), recombinant human transferrin (concentration is 100ng / mL) and the BMPR1B inhibitor of the present invention (induction medium A uses BMPR1B inhibitor II-1, and induction medium B uses BMPR1B inhibitor II-13).

[0176] (2) Expansion and passage of pluripotent stem cells

[0177] Commercial human pluripotent stem cell lines H1, H9 and induced pluripotent stem cell (iPSC) lines were used for the preparation. Induced pluripotent stem cells were obtained by reprogramming using CD34+ cells according to the "reprogramming medium, i.e., a method for culturing induced pluripotent stem cells" (CN109628383A, Example 2). Matrigel (STEMCELL Technologies) was used to coat T25 cell culture flasks, which were plated and incubated in a 37°C incubator for more than one hour. The cells were cultured at 1×10 6 The cells were seeded in T25 culture flasks for expansion and subculture.

[0178] (3) Neural induction

[0179] 6-well culture plates were coated with 50 μg / mL poly-lysine (SIGMA, catalog number: P6407) and incubated in a 37°C incubator for more than 3 hours after plating; then 5 μg / mL laminin (SIGMA ALDRICH, catalog number: I2020) was further coated and incubated in a 37°C incubator for more than 3 hours after plating. When the pluripotent stem cells reached 70% coverage, they were digested with EDTA at 37°C for 5 minutes and DMEM was used to terminate cell digestion. After washing and centrifugation, the cells were incubated at 2×10 5The ratio of each bottle was re-seeded in a T25 culture plate. The above-mentioned induction medium was used for induction. Specifically, the pluripotent stem cells H9 were induced with induction medium A, and the pluripotent stem cells H1 and induced pluripotent stem cells were induced with induction medium B, respectively. The medium was changed every day until the 14th day.

[0180] (4) Sequence detection and data analysis and processing

[0181] Samples were taken on the 7th and 14th days of induction, and the samples were processed using the VAHTS Universal V8 RNA-seq LibraryPrep Kit for Illumina (Vazyme, NR605-01 / 02), and sequence detection was performed using Illumina. After obtaining the raw sequencing data, FASTP, HISAT2, and FeatureCounts were used to process the data in turn to obtain the expression level of the gene. GAPDH was used as a reference gene to calibrate the mRNA expression level of different batches of transcriptomes.

[0182] The analysis found that as the concentration of BMPR1B inhibitor II-1 increased, the expression of NANOG, a marker gene of pluripotent stem cells H9, treated with BMPR1B inhibitor, decreased (P<0.05, t-test). At the same time, the expression of PAX6, a marker gene of neural progenitor cells, increased (P<0.05, t-test). This indicates that the system exhibited a dose-dependent effect on II-1 during the induction process. From the 7th day to the 14th day, as the induction time increased, the expression of NANOG decreased while the expression of PAX6 increased ( Figure 3 , error bars represent the standard deviation of three biological replicates). These results indicate that the BMPR1B inhibitor II-1 provided by the present invention has the effect of promoting the differentiation of pluripotent stem cells into neural progenitor cells ( Figure 4 B, D).

[0183] In addition, as the concentration of BMPR1B inhibitor II-13 increased, the expression of neuronal marker gene MAP2 (A. Caceres, Developmental Brain Research. Volume 13, Issue 2, April 1984, Pages 314-318) and glial progenitor cell marker gene Sox9 (Neyrinck, K et al., Stem Cell Rev and Rep 17, 185521)) in pluripotent stem cells H1 treated with BMPR1B inhibitor showed a dose-dependent effect on II-13 ( Figure 5 ).

[0184] Furthermore, compared with the induced pluripotent stem cells in the control group that were not treated with the BMPR1B inhibitor, the expression of key genes such as neuronal precursor marker genes Sox1, Sox5 (Elkouris M et al., Stem Cells. 2011; 29(1):89–98; Tina Lai et al., Neuron V57(2):232-247, 2008) and nervous system differentiation marker gene VIM (Sofia Duarte et al., Nature Communications volume 10, 4200(2019)) in the induced pluripotent stem cells treated with the BMPR1B inhibitor II-13 was significantly increased, also showing a dose-dependent effect on II-13 ( Figure 6 ). These results indicate that the BMPR1B inhibitor provided by the present invention can not only promote the differentiation of pluripotent stem cells into neural progenitor cells, but also has the effect of promoting the formation and differentiation of various neural cells.

[0185] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0186] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the invention patent. For those of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached claims, and the description and drawings may be used to interpret the content of the claims.

Claims

1. An induction medium comprising a BMPR1B inhibitor; The BMPR1B inhibitor has a structure as shown in Formula I, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled, isomer or prodrug of the structure as shown in Formula I; in, Ring A is selected from any of the following structures: Y is -(CH2) n -, n is 0, 1, 2 or 3; R 1 Selected from -H, -D, unsubstituted or R 2 Substituted C1-C6 alkyl, C1-C6 alkoxy, C6-C 10 Aryl or C3~C 10 heteroaryl; R 2 Selected from -F, -Cl, -Br, -I, -OH, -COOH, C1-C6 alkyl or C1-C6 alkoxy; "*" indicates the attachment site.

2. The induction medium according to claim 1, characterized in that The BMPR1B inhibitor meets one or more of the following conditions: (1) Y is -(CH2) n -, n is 0, 1 or 2; (2)R 1 Selected from -H, -D, unsubstituted or R 2 Substituted C1-C6 alkyl, C6-C 10 Aryl or C3~C 10 heteroaryl; (3)R 2 Selected from -OH or C1~C6 alkyl.

3. The induction medium according to claim 2, characterized in that The BMPR1B inhibitor meets one or more of the following conditions: (1) Y is -(CH2) n -, n is 0 or 1; (2)R 1 Selected from -H, -D, unsubstituted or R 2 Substituted C3-C6 heteroaryl; (3)R 2 Selected from -OH or C1~C4 alkyl.

4. The induction medium according to claim 3, characterized in that The BMPR1B inhibitor meets one or more of the following conditions: (1) Y is -(CH2) n -, n is 0 or 1; (2)R 1 Selected from -H, -D, unsubstituted or R 2 substituted furan, thiophene, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, pyran, thiopyran, pyridine, pyridazine or pyrimidine; (3)R 2 Selected from -OH, methyl, ethyl, n-propyl or isopropyl.

5. The induction medium according to any one of claims 1 to 4, characterized in that R 1 Selected from -H, -D or any of the following substituents: Wherein, "*" indicates the connection site.

6. The induction medium according to any one of claims 1 to 4, characterized in that The BMPR1B inhibitor has a structure shown in any one of Formulas I-1 to I-13, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled, isomer or prodrug of the structure shown in any one of Formulas I-1 to I-13; 7. The induction medium according to any one of claims 1 to 4, characterized in that The BMPR1B inhibitor has a structure shown in Formula II, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled, isomer or prodrug of the structure shown in Formula II; Among them, ring A, Y and R 1 As defined in any one of claims 1 to 4.

8. The induction medium according to any one of claims 1 to 4, characterized in that The BMPR1B inhibitor has a structure shown in any one of Formulas II-1 to II-13, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled, isomer or prodrug of the structure shown in any one of Formulas II-1 to II-13; 9. The induction medium according to any one of claims 1 to 4, characterized in that The concentration of the BMPR1B inhibitor is 1 μM to 50 μM.

10. The induction medium according to any one of claims 1 to 4, characterized in that The induction medium further comprises one or more of a basal medium, growth factors, inorganic salts and additives; Wherein, the growth factors include one or more of vitamins, progesterone, 1,4-butanediamine and insulin; The additives include one or more of piperidinol oxide, luteolin, D(+)-galactose and recombinant human transferrin.

11. The induction medium according to claim 10, characterized in that The induction medium meets one or more of the following conditions: (1) The basal medium is DMEM medium or DMEM-F12 medium, and the basal medium is supplemented with minimum essential medium non-essential amino acids; (2) The vitamins include one or more of vitamin E, vitamin B12 and vitamin C; (3) The inorganic salt includes one or more of sodium chloride and sodium selenite.

12. The induction medium according to claim 11, characterized in that The induction medium meets one or more of the following conditions: (1) The growth factors include vitamins, 2.0 ng / mL to 15 ng / mL of progesterone, 2 μg / mL to 50 μg / mL of 1,4-butanediamine, and 5 mg / L to 40 mg / L of insulin, and the vitamins include 0.1 μg / mL to 15 μg / mL of vitamin E, 0.5 μM to 2.4 μM of vitamin B12, and 32 mg / L to 128 mg / L of vitamin C; (2) The inorganic salts include 0.5 g / L sodium chloride and 13.6 μg / L sodium selenite; (3) The additives include 10 μM to 200 μM piperidinol oxide, 5 μM to 150 μM luteolin, 5 μg / mL to 25 μg / mL D(+)-galactose, and 50 ng / mL to 200 ng / mL recombinant human transferrin.

13. A method for inducing pluripotent stem cells to differentiate into neural lineage cells, comprising the following steps: Adhesion culture of pluripotent stem cells using the induction medium described in any one of claims 1 to 12 to obtain neural lineage cells.

14. Use of the BMPR1B inhibitor in the induction medium according to any one of claims 1 to 12 in inducing differentiation of pluripotent stem cells into neural lineage cells.

Citation Information

Cited By

  • Compound for maintaining stemness of stem cells and organoid culture and application thereof

    CN122234056A

  • Compounds for maintaining stem cell stemness and organoid culture and uses thereof

    CN122234056B